ArticleScientific reports2025
RBM10 suppresses colorectal cancer invasion by regulating LncRNA SNHG17 alternative splicing.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
To explore the role of RBM10 in colorectal cancer (CRC) and the regulatory mechanism of CRC invasion through alternative splicing (AS) of long non-coding RNA (lncRNA) SNHG17 by RBM10. Samples were collected from sixty cases of CRC and their corresponding adjacent normal tissues. Immunohistochemistry and Western blot were performed to analyze the expression of RBM10. A Transwell invasion assay was conducted to evaluate the effect of RBM10 on the invasion of HCT116 cells, and a Western blot was performed to detect the expression of EMT-related proteins. Moreover, CLIP-seq and RIP experiments were performed to explore the interaction between RBM10 and SNHG17. The expression of RBM10 was significantly decreased in CRC tissues and cells compared to the normal adjacent tissues. Overexpression of RBM10 inhibited CRC invasion, while knockdown of RBM10 had the opposite effect. RBM10 was found to interact with SNHG17 and regulate its splice isoform balance. Specifically, the splice variant SNHG17_2 regulated by RBM10 was upregulated in CRC and was positively correlated with CRC invasion. RBM10 inhibits CRC invasion by regulating the alternative splicing of SNHG17, providing new research directions and potential targets for CRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.